Feasibility of Community Pharmacist-Initiated and Point-of-Care <i>CYP2C19</i> Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors

Feasibility of Community Pharmacist-Initiated and Point-of-Care <i>CYP2C19</i> Genotype-Guided De-Escalation of Oral P2Y12 Inhibitors

Tailoring antiplatelet therapy based on <i>CYP2C19</i> pharmacogenetic (PGx) testing can improve cardiovascular outcomes and potentially reduce healthcare costs in patients on a P2Y<sub>12</sub>-inhibitor regime with prasugrel or ticagrelor. However, ubiquitous adoption—parti...

Full description

Bibliographic Details
Main Authors: Amar D. Levens, Melina C. den Haan, J. Wouter Jukema, Mette Heringa, Wilbert B. van den Hout, Dirk Jan A. R. Moes, Jesse J. Swen
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Genes
Subjects:
<i>CYP2C19</i>
pharmacogenetics
pharmacogenomics
P2Y<sub>12</sub> inhibitor
clopidogrel
personalized medicine
Online Access:https://www.mdpi.com/2073-4425/14/3/578

Internet

https://www.mdpi.com/2073-4425/14/3/578

Similar Items